Ozempic, a diabetes drug, has been introduced in India by Novo Nordisk, marking a significant advancement in diabetes treatment. The Managing Director of Novo Nordisk India, Vikrant Shrotriya, emphasizes the drug's potential to address the challenges of diabetes management in the country, where over 100 million adults live with type 2 diabetes. Ozempic offers a more comprehensive approach to diabetes care, addressing the limitations of existing therapies that often fail to control blood sugar levels and may lead to weight gain. It can reduce HbA1c levels by up to 2.8% while supporting weight loss, providing a more holistic treatment option for patients. However, it's crucial to manage expectations and address misconceptions. While Ozempic is known for its weight loss effects and has gained attention from celebrities, it is not a miracle cure. The science behind the drug remains controlled, and misinformation can lead to fear-driven narratives that may discourage patients who need it. Novo Nordisk emphasizes the importance of medical supervision and patient education to prevent self-medication and misuse. Safety concerns, such as side effects like gastric issues, kidney problems, or pancreatitis, are carefully evaluated, and the benefits of Ozempic clearly outweigh the risks when used correctly. The company also advocates against the misuse of the drug for cosmetic or off-label purposes, ensuring that it is prescribed and accessed through legitimate channels. In the Indian market, Ozempic is priced affordably, around Rs 2,200 per week, making it accessible to a wider range of patients. However, affordability alone is not enough; addressing gaps in awareness and diagnosis, especially in rural areas, is essential for the drug's impact. Novo Nordisk views competition from Eli Lilly's Mounjaro as a public health challenge rather than a market rivalry, focusing on the need to manage diabetes and obesity effectively. The introduction of Ozempic in India is a potential turning point, with the potential to significantly impact the diabetes and obesity landscape if used responsibly.
